Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 13/20 | 0.51 |
| ▸ | DRD2 | P14416 | 11/20 | 0.51 |
| ▸ | F3 | P13726 | 10/20 | 0.51 |
| ▸ | DRD3 | P35462 | 8/20 | 0.51 |
| ▸ | DRD5 | P21918 | 5/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910671 | 1.00 | DRD1 (0.51) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL2742599 | 0.90 | DRD1 (0.55) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL910222 | 0.88 | DRD1 (0.56) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL29999760 | 0.88 | DRD1 (0.56) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL910002 | 0.88 | DRD1 (0.58) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL30000305 | 0.88 | DRD1 (0.58) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL29999897 | 0.85 | DRD1 (0.55) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL910675 | 0.85 | DRD1 (0.55) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL23206839 | 0.85 | DRD1 (0.51) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL29999932 | 0.85 | DRD1 (0.70) | DRD1DRD2F3DRD3DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | DRD1 4727/4885DRD2 4557/4885F3 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.